Lead Product(s) : UB-621
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Shanghai Public Health Clinical Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UB-621 is a first-in-class anti-gD mAb a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).
Product Name : UB-621
Product Type : Antibody
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : UB-621
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Shanghai Public Health Clinical Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ISPM21
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GS-441524 (named ISPM21) is main plasma metabolite of the antiviral prodrug remdesivir. Studies on inhalable liposomal ISPM21 showed significantly higher concentrations in the lungs than their conventional counterparts.
Product Name : GS-441524
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2021
Lead Product(s) : ISPM21
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-621
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The current Phase 2 study is a randomized, single-blinded, placebo-controlled study to investigate the efficacy and safety of single dose UB-621 treatment for recurrent genital herpes.
Product Name : UB-621
Product Type : Antibody
Upfront Cash : Inapplicable
November 11, 2020
Lead Product(s) : UB-621
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)
Details : In preclinical studies, TLC19 demonstrated 30-fold exposure in the lungs while achieving lower blood and heart exposure than oral HCQ and unformulated HCQ.
Product Name : TLC19
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S-2P Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : S-2P Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000
Details : TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.
Product Name : TG-1000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2020
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000
Details : TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.
Product Name : TG-1000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable